Globus Medical's FY16 Sales Guidance Tempers Q4, FY15 Above-The-Street Outlook

Traders in shares of Globus Medical Inc GMED are offering down the stock in Wednesday's after-hours session following some mixed preliminary results.

After closing up 2 percent at $27.61, the stock last traded at $26 even, down nearly 6 percent from the end of intraday trade.

The company said it's expecting fourth quarter revenue around $142.6 million, better than the analyst consensus estimate of just $139 million.

Looking ahead to the annual results, Globus Medical said its anticipating sales of about $544.7 million, up from the previously issued $539 million and slightly above the Street expectation of $541 million.

As is often the case, investors seem to have deemed the furthest-looking guidance figure as the most important. Fiscal-year 2016 sales are expected around $583 million, below the current analyst estimate of $590 million. Earnings are expected around $1.20 per share, very modestly above the sell-side estimate of $1.19.

"2016 EPS guidance reflects an increase in net income in line with our expected sales growth, as well as a positive contribution from the recently-announced suspension of the Medical Device Tax," Dan Scavilla, the company's CFO, said. "Our 2016 guidance reflects approximately 7% growth in sales and 10% growth in EPS over our expected 2015 results."

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceAfter-Hours CenterMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!